Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this trial is to explore the efficacy of HuMax-CD4 treatment with respect to tumor response and duration in patients with refractory or relapsed non-cutaneous CD4+ T-cell lymphoma.
Critère d'inclusion
- The mature non-cutaneous T-cell lymphomas expressing the CD4 molecule are the object of this protocol. 1.Peripheral T-cell lymphoma (PTCL) unspecified 2.Angioimmunnoblastic T-cell lymphoma 3.Anaplastic large cell lymphoma 4.Enteropathy type T-cell lymphoma 5.Hepatosplenic T-cell lymphoma